FDA grants fast track status to Allogeneās autoimmune therapy
Allogene Therapeutics, a biotech company, has received “Fast Track” status from the U.S. Food and Drug Administration (FDA) for its new therapy, ALLO-329, aimed at treating autoimmune diseases like systemic lupus erythematosus (SLE), immune-mediated inflammatory diseases (IIM), and systemic sclerosis (SSc). This designation is granted to expedite the development and review of drugs that address […]
